Beiley Biofund
Overview
Beiley Biofund is a venture capital firm dedicated to advancing life sciences by partnering with innovators to develop breakthrough therapies and technologies that address unmet medical needs.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Libo Pharma Corp. | Jul 2025 | Series C | Co-investor |
| VerImmune | Sep 2024 | VC Round | Lead |
| Ascendo Biotechnology | Apr 2026 | Series A | Co-investor |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Beiley Biofund based?
Beiley Biofund is headquartered in Taipei, Taiwan.
When was Beiley Biofund founded?
Beiley Biofund was founded in 2024.
How many portfolio companies does Beiley Biofund have?
Beiley Biofund has 3 portfolio companies in Caplight's dataset.
What are some companies in Beiley Biofund's portfolio?
Portfolio companies visible on Caplight include Libo Pharma Corp., VerImmune, Ascendo Biotechnology.
What was Beiley Biofund's most recent investment shown here?
Beiley Biofund's most recent investment in this portfolio sample was in Ascendo Biotechnology in 2026.
What sectors does Beiley Biofund focus on?
Beiley Biofund focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences.
What company stages does Beiley Biofund focus on?
Stage focus information for Beiley Biofund is not publicly available.
What is Beiley Biofund's AUM?
Beiley Biofund's assets under management are estimated between $66.0M and $66.0M.